Lund, Sweden

Claes Schalén

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Neobiotics Ab. Active years: 2010-2012.

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2010-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Claes Schalén: Innovator in Antimicrobial Agents

Introduction

Claes Schalén is a notable inventor based in Lund, Sweden. He has made significant contributions to the field of antimicrobial agents, holding a total of 2 patents. His work focuses on developing innovative compounds that can be used in medical applications.

Latest Patents

Schalén's latest patents include "Peptide derivatives useful as antimicrobial agents and for treating wounds." This patent describes a compound with the general formula (I) R—NH—CH[(CH)—NH—C(NH)—NH]-CO—R-A-R. The compound is utilized in pharmaceutical compositions for treating microbial diseases and stimulating eukaryotic cells. Another patent titled "Antimicrobial compounds" relates to compositions comprising a compound based on the general formula (I) R-Arg-R—NH—CH(R)—CH—NH—R—(I) along with a carrier, diluent, or excipient.

Career Highlights

Claes Schalén is associated with Neobiotics AB, where he continues to advance his research in antimicrobial solutions. His work has the potential to impact the medical field significantly, particularly in the treatment of infections and wound care.

Collaborations

Some of his notable coworkers include Anders Grubb and Regina Kasprzykowska. Their collaborative efforts contribute to the innovative research being conducted at Neobiotics AB.

Conclusion

Claes Schalén is a prominent inventor whose work in antimicrobial agents showcases his commitment to advancing medical science. His patents reflect a dedication to developing effective treatments for microbial diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…